ALK and non-small cell lung carcinoma: Efficacy with brigatinib was consistently better than with crizotinib in Asian and non‐Asian patients with locally advanced or metastatic ALK inhibitor‐naive ALK− + NSCLC. There were no clinically notable differences in overall safety in Asian vs. non‐Asian patients